Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

BACKGROUND: Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated the possibility of blocking oncogenic signaling of NRAS by inhibiting two...

Descripción completa

Detalles Bibliográficos
Autores principales: Atefi, Mohammad, Titz, Bjoern, Avramis, Earl, Ng, Charles, Wong, Deborah JL, Lassen, Amanda, Cerniglia, Michael, Escuin-Ordinas, Helena, Foulad, David, Comin-Anduix, Begonya, Graeber, Thomas G, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320814/
https://www.ncbi.nlm.nih.gov/pubmed/25645078
http://dx.doi.org/10.1186/s12943-015-0293-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320814/
https://www.ncbi.nlm.nih.gov/pubmed/25645078
http://dx.doi.org/10.1186/s12943-015-0293-5

Ejemplares similares